Clinical Trial News and Research

RSS

Medgenics’ phase I/II clinical trial shows EPODURE continuous anemia treatment lasting 5 months in kidney disease patients

Medgenics has announced that the latest, encouraging results of the Company's ongoing EPODURE Biopump Phase I/II Clinical Trial were presented at the 45th Conference of the Israeli Society of Nephrology and Hypertension, in Israel on March 27, 2009.

29 Mar 2009

Eli Lilly announces inconclusive study results for mGlu2/3 in acute schizophrenia

Eli Lilly and Company has announced inconclusive Phase II clinical trial results from Study HBBI investigating LY2140023 monohydrate, also known as mGlu2/3, for the treatment of patients suffering from acute schizophrenia.

29 Mar 2009

A comparative analysis of four beta blocker trials

ARCA biopharma, Inc. has announced that a comparative analysis of primary endpoint data from four beta blocker trials was presented at the American College of Cardiology 58th Annual Scientific Session being held March 29-31, 2009.

29 Mar 2009

Trial reinforces safety and efficacy of Boston Scientific's two drug-eluting stent platforms

Boston Scientific Corporation has welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials.

29 Mar 2009

Amicus Therapeutics presents positive results from phase 2 extension study of Amigal for Fabry disease

Amicus Therapeutics has announced positive results from its ongoing Phase 2 extension study of its investigational drug, Amigal (migalastat HCL) for Fabry disease.

29 Mar 2009

RegeneRx reports phase II venous stasis trial results

Regenerx Biopharmaceuticals Inc. has announced the results of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers.

29 Mar 2009

Positive phase 3 uveitis trial results for voclosporin

Isotechnika Inc. has announced that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ or LX211) for the treatment of uveitis.

29 Mar 2009

Add-on treatment may reduce treatment-associated weight gain caused by antipsychotic treatments

Antipsychotic drugs, such as olanzapine (Zyprexa), risperidone (Risperdal) and quetiapine (Seroquel), are commonly used to treat psychotic disorders like schizophrenia, but also bipolar disorder and even behavioral problems related to dementia.

29 Mar 2009

Rexahn Pharmaceuticals starts phase II pancreatic cancer trial

Rexahn Pharmaceuticals, Inc. has announced that it has received FDA approval to begin Phase II trials for Archexin, the Company's leading cancer compound, for the treatment of pancreatic cancer.

24 Mar 2009

Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes

Radius Health ("Radius") announced today that the first patient has been dosed in the company's proof-of-concept Phase 2a study of RAD1901, an investigational selective estrogen receptor modulator (SERM) undergoing clinical evaluation for treatment of vasomotor symptoms (menopausal hot flashes).

24 Mar 2009

Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension

Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase II clinical trial of cicletanine hydrochloride (cicletanine), an oral agent in development for the treatment of pulmonary arterial hypertension (PAH).

24 Mar 2009

Experimental Parkinson's therapy may have robust weight-loss effect

A growth factor used in clinical experiments to rescue dying brain cells in Parkinson patients may cause unwanted weight loss if delivered to specific areas of the brain, according to University of Florida researchers in the March online edition of Molecular Therapy.

24 Mar 2009

Canadian researchers to launch clinical trial to determine efficacy of treating latent TB with four-month course of Rifampin

Researchers at McGill University in Montreal on Tuesday announced they will soon launch an international clinical trial to determine if latent tuberculosis can be treated successfully with a four-month treatment course of the TB drug rifampin rather than the standard nine-month treatment with the TB drug isoniazid, the CP/Toronto Sun reports.

24 Mar 2009